Abbott Launches Flexible XIENCE Skypoint Stent in India

Abbott has unveiled its most advanced generation stent, XIENCE Skypoint, in India. The new stent is part of the globally trusted XIENCE family of everolimus-eluting coronary stents and is designed to offer greater flexibility, ease of navigation, and improved treatment options for complex heart blockages.

Tushar Sharma, General Manager of Abbott’s vascular business in India and South Asia, stated, “The launch of XIENCE Skypoint in India represents an advancement for doctors treating cardiovascular disease, which remains a leading cause of mortality in India. Many patients today develop severe blockages earlier in life due to rising hypertension, diabetes, cholesterol, and lifestyle risks.

This makes it essential to support doctors with stents that can safely reach difficult areas and treat a wide range of blockages. XIENCE Skypoint brings improvements with precision and strengthens our commitment to providing advanced heart treatments across the country.”

Also Read: Advancing Interventional Radiology in India Through Collaboration

The XIENCE Skypoint platform brings the broadest size matrix ever offered by the XIENCE family, with new 4.5 mm and 5.0 mm diameters. It is the only drug-eluting stent (DES) indicated for vessels up to 5.25 mm, making it highly effective for patients with larger or more varied artery sizes. Additionally, the stent offers the option to treat longer lesions with a single 48 mm stent, reducing procedure time, radiation exposure, and contrast dye usage.

Backed by over 120 clinical trials and more than 20 million implants globally, XIENCE Skypoint builds on the established safety and durability of the XIENCE legacy, continuing Abbott’s commitment to heart health innovation.